Centocor launches corporate blog

Share this article:
Katz: leading Centocor into blogosphere
Katz: leading Centocor into blogosphere

Centocor launched itself into the blogosphere with the debut of its corporate blog at cnto411.com.

Centocor spokeswoman Melissa Katz told MM&M the corporate blog aims to serve as a forum for discussion on issues relevant to the industry and not a platform for sounding off on Centocor products.
 
“I plan on posting to the blog as often as I can on issues that are relevant, hopefully a couple of times a week,” Katz said. Michael Parks, VP of corporate comms and executive producer of Centocor's unbranded feature length film Innerstate, will serve in the role the blog's guest author.

“Around the time of Innerstate's debut about a year ago, we realized that we weren't paying enough attention to the blogosphere,” Katz said. “Since then we have been working with those bloggers to see how we can better communicate with them.”

Centocor, joins its parent company Johnson & Johnson which began corporate blogging with jnjbtw.com last summer. J&J's blog, edited by spokesman Marc Monseau, has taken a similar tack as a forum for discussion of non-product specific, industry related issues.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...